Annals of Surgical Oncology, Vol 3, Issue 2 176-184, Copyright © 1996 by Society of Surgical Oncology

ARTICLES

In situ cytokine production by breast cancer tumor-infiltrating lymphocytes

B. J. Camp, S. T. Dyhrman, V. A. Memoli, L. A. Mott and R. J. Barth Jr
Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.

BACKGROUND: Human breast cancers progressively grow despite the presence of extensive lymphocytic infiltration and specific antitumor immune recognition, thereby calling into question the competency of breast tumor-infiltrating lymphocytes (TIL). The function of breast TILs in vivo and their possible role in the suppression of an antitumor immune response are largely unknown. METHODS: The cytokines produced in situ by lymphocytes in 89 breast carcinomas and 14 benign breast lesions were assessed using immunohistochemistry. RESULTS: The majority of tumor and benign breast samples contained T-cell infiltrates, which were disclosed using an anti-CD3 antibody stain. The percentage of tumor samples in which > or =3% of the lymphocytes were producing cytokines was as follows: interleukin (IL)-2 45%, IL-4 36%, tumor necrosis factor-alpha (TNF-alpha) 28%, transforming growth factor-beta 1 (TGF-beta 1) 20%, IL-10 11%, interferon-gamma (IFN-gamma) 4%, and granulocyte-macrophage colony-stimulating factor (GM-CSF) 3%. Production of IL-2, IL-4, and TGF-beta 1 by TILs in breast cancers exceeded that detected in benign breast lesions (p < 0.005). Significantly more tumor samples contained lymphocytes producing IL-2, IL-4, TGF-beta 1, and TNF-alpha than IFN-gamma and GM-CSF (p < 0.002 for each comparison). One or more of the potentially immunoinhibitory cytokines-IL-4, IL-10, or TGF-beta 1-were produced by lymphocytes in 44% of the specimens. No significant associations were seen between lymphocyte production of a particular cytokine and disease-free survival (median follow-up 43 months). CONCLUSIONS: Immunohistochemical techniques can be used to detect cytokine secretion by TILs in preserved tissue. The relative lack of secretion of IFN-gamma and GM-CSF, rather than a deficiency of IL-2, may explain why the antitumor immune response to breast cancer is impaired.

This article has been cited by other articles:

				A. Jewett, C. Head, and N.A. Cacalano Emerging Mechanisms of Immunosuppression in Oral Cancers. J. Dent. Res., December 1, 2006; 85(12): 1061 - 1073. [Abstract] [Full Text] [PDF]

				M R Hussein and H I Hassan Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J. Clin. Pathol., September 1, 2006; 59(9): 972 - 977. [Abstract] [Full Text] [PDF]

				C. Conticello, F. Pedini, A. Zeuner, M. Patti, M. Zerilli, G. Stassi, A. Messina, C. Peschle, and R. De Maria IL-4 Protects Tumor Cells from Anti-CD95 and Chemotherapeutic Agents via Up-Regulation of Antiapoptotic Proteins J. Immunol., May 1, 2004; 172(9): 5467 - 5477. [Abstract] [Full Text] [PDF]

				S. C. Robinson, K. A. Scott, J. L. Wilson, R. G. Thompson, A. E. I. Proudfoot, and F. R. Balkwill A Chemokine Receptor Antagonist Inhibits Experimental Breast Tumor Growth Cancer Res., December 1, 2003; 63(23): 8360 - 8365. [Abstract] [Full Text] [PDF]

				E. Azenshtein, G. Luboshits, S. Shina, E. Neumark, D. Shahbazian, M. Weil, N. Wigler, I. Keydar, and A. Ben-Baruch The CC Chemokine RANTES in Breast Carcinoma Progression: Regulation of Expression and Potential Mechanisms of Promalignant Activity Cancer Res., February 1, 2002; 62(4): 1093 - 1102. [Abstract] [Full Text] [PDF]

				A. W. Tong, M. H. Papayoti, G. Netto, D. T. Armstrong, G. Ordonez, J. M. Lawson, and M. J. Stone Growth-inhibitory Effects of CD40 Ligand (CD154) and Its Endogenous Expression in Human Breast Cancer Clin. Cancer Res., March 1, 2001; 7(3): 691 - 703. [Abstract] [Full Text]

				A. Moore, E. Marecos, A. Bogdanov Jr, and R. Weissleder Tumoral Distribution of Long-circulating Dextran-coated Iron Oxide Nanoparticles in a Rodent Model Radiology, February 1, 2000; 214(2): 568 - 574. [Abstract] [Full Text]

				G. Luboshits, S. Shina, O. Kaplan, S. Engelberg, D. Nass, B. Lifshitz-Mercer, S. Chaitchik, I. Keydar, and A. Ben-Baruch Elevated Expression of the CC Chemokine Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) in Advanced Breast Carcinoma Cancer Res., September 1, 1999; 59(18): 4681 - 4687. [Abstract] [Full Text] [PDF]